Neuraxis (NRXS) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Stereotaxis (STXS) over the past year, gaining 116.3% versus a loss of 67.1%. Stereotaxis is the larger company by market cap ($111.2 million vs $87.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXS | STXS |
|---|---|---|
| Share price | $6.93 | $1.11 |
| Market cap | $87.03M | $111.22M |
| 1-day change | +2.36% | 0.00% |
| YTD return | +49.12% | -51.74% |
| 1-year return | +116.29% | -67.06% |
| 5-year return | — | -81.28% |
| EPS (TTM) | $-0.78 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.33 | $3.42 |
| 52-week low | $2.21 | $1.09 |
| Distance from 52-week high | -25.72% | -67.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +58.73% | +170.27% |
| Average volume | 107.27K | 808.41K |
| Shares outstanding | 12.56M | 100.20M |
| Employees | 24 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed STXS by 183.4 percentage points over the past year.
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
NRXS vs STXS FAQ
Which is bigger, Neuraxis or Stereotaxis?
Stereotaxis (STXS) is larger, with a market capitalization of $111.22M compared with $87.03M for Neuraxis (NRXS).
Which stock has performed better over the past year, NRXS or STXS?
NRXS returned +116.29% over the past 12 months, compared with -67.06% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are Neuraxis and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.